Organization
Jiangsu Ascentage Pharma Pty Ltd.
1 abstract
Abstract
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).Org: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group, Jiangsu Ascentage Pharma Pty Ltd.,